由于Viking Therapeutics(VKTX.US)旗下实验性口服减肥药的中期试验数据不及预期截至发稿该股周二美

智通财经
Aug 19
由于Viking Therapeutics(VKTX.US)旗下实验性口服减肥药的中期试验数据不及预期截至发稿该股周二美股盘前暴跌近34%。Viking在一份声明中表示其口服GLP-1R/GIPR双重激动剂VK2735帮助患者减重最多可达12.2%。然而在短短三个月内约28%的患者退出了试验。这打击了人们对该药物能够与礼来(LLY.US)、诺和诺德(NVO.US)的药物竞争的信心。瑞穗证券的分析师Jared Holz表示:“需要注意的是患者在13周内停药的比例如此之高。”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10